

August 9, 2021

Nancy Lurker
Chief Executive Officer
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown, MA 02472

Pharmaceuticals, Inc.
Statement on Form S-3
2021

Re: EyePoint
Registration
Filed August 6,
File No. 333-258598

Dear Ms. Lurker:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Park at 202-551-7439 with any questions.

Please contact Jane

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc:

Stephen Nicolai, Esq.